<DOC>
	<DOCNO>NCT01572792</DOCNO>
	<brief_summary>The purpose Phase III study evaluate long-term safety tolerability two fixed-dose combination inhale aclidinium bromide/formoterol fumarate , aclidinium bromide , formoterol fumarate placebo patient moderate severe Chronic Obstructive Pulmonary Disease ( COPD ) . Long-term efficacy , pharmacoeconomic health-related quality life assessment also evaluate . This extension study include 28 week treatment period , follow four week follow visit . All patient remain treatment group lead-in study continue one four treatment arm placebo .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Two Fixed Dose Combinations Aclidinium Bromide/Formoterol Fumarate , Aclidinium Bromide , Formoterol Fumarate Placebo 28-Weeks Treatment Patients With Moderate Severe , Stable Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Completion treatment phase leadin study , LACMD31 Written inform consent obtain patient initiation study specific procedures No medical contraindication judge PI Compliance LACMD31 study procedure IP dose . No specific exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Airflow Obstruction , Chronic</keyword>
	<keyword>Chronic Airflow Obstruction</keyword>
	<keyword>Chronic Obstructive Airway Disease</keyword>
	<keyword>Chronic Obstructive Lung Disease</keyword>
</DOC>